Skip to content

Efficacy: Change in Nail Psoriasis Severity Index after 16 weeks of treatment

Patients with nail psoriasis can develop a wide variety of nail ch. Although topical therapy is widely used, studies on efficacy are limited. After 16 weeks, the mean percentage improvement in the NAPSI score in target fingernails was significantly higher among patients treated with adalimumab than among patients in the placebo group (50 versus 8 percent). OBJECTIVE: We sought to evaluate efficacy of apremilast in nail/scalp psoriasis in ESTEEM 1 and 2. At week 16, apremilast produced greater improvements in Nail Psoriasis Severity Index score versus placebo; mean percent change: -22.5 versus +6. The Nail Psoriasis Severity Index (NAPSI) has been developed as an objective and reproducible tool, which helps to estimate the nail involvement and therefore to standardize the treatment outcome assessments. Psoriatic changes of the nail unit can also be triggered by minor traumas such as manicure, biting the nails, picking or trimming the cuticle, clearing subungual debris, or wearing tight-fitting shoes. In a RCT of palmoplantar psoriasis, 28 of 36 patients with nail involvement received adalimumab therapy for 16 weeks and showed a higher mean percentage of NAPSI improvement compared to placebo-treated group (50 versus 8 ). After longer term safety and efficacy are proven, ustekinumab could become an effective option for treatment of nail psoriasis.

Efficacy: Change in Nail Psoriasis Severity Index after 16 weeks of treatment 2OTEZLA improved the severity of palmoplantar psoriasis at week 16 in a subset of patients across three trials. Long-term safety profile for up to 104 weeks in ESTEEM 1 was consistent with previously reported data from OTEZLA clinical trial programs, with no new safety signals and no clinically meaningful changes in laboratory values. This superiority was already present after 16 weeks of treatment. For patients with nail psoriasis at baseline, mean percent change from baseline in target Nail Psoriasis Severity Index (NAPSI) score at week 16 (placebo-controlled phase, period A) and week 32 (maintenance phase, period B) in Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis (ESTEEM) 1 (A) and ESTEEM 2 (B), and mean percent change in target nail NAPSI score by Psoriasis Area and Severity Index (PASI) response at week 16 (period A) in patients treated with apremilast 30 mg twice daily (BID) in ESTEEM 1 and ESTEEM 2 (C).

Nail psoriasis can be treated effectively using topical treatments, intralesional treatments, and systemic treatments, but an optimal effect may take up to 1 year. Most recent studies on nail psoriasis use the Nail Psoriasis Severity Index (NAPSI), target NAPSI, or one of its many variants as a marker of nail improvement 23. Psoriatic nail changes can be provoked by minor traumas, such as nail biting, subungual cleaning, picking, or manicure. The drug has been proven effective in moderate to severe psoriasis in previous phase 3 trials. Survival After Multiple Melanomas Is Worse Than After a Single Melanoma. Efficacy assessments were performed on the target fingernail by means of the modified Nail Psoriasis Severity Index score. This superiority was already present after 16 weeks of treatment. Moreover, the analysis of the modified Nail Psoriasis Severity Index-50 showed a statistically significant clinical improvement after 12 weeks of treatment in comparison to the results obtained after 8 weeks (Fisher& 39;s exact test, P<0.

Oral (apremilast) Long-term Safety And Efficacy Data In Patients With Moderate To Severe Plaque Psoriasis Presented At Aad (nasdaq:celg)

Treatment of nail psoriasis includes different types of medications, from topical therapy to systemic therapy, according to the severity and extension of the disease. The most severe changes are observed when the disease affects the nail matrix, a germinative epithelium that produces the nail plate. The only validated method to diagnose nail psoriasis is the NAPSI (Nail Psoriasis Severity Index), which is the most commonly used worldwide. Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important. At week 16 of ESTEEM 1 and ESTEEM 2 studies, patients experienced:. Efficacy: Change in Nail Psoriasis Severity Index after 16 weeks of treatment. Responses and adverse effects of one selected target nail were recorded at screening, at baseline and at weeks 2, 4, 8 and 12 of treatment with a final assessment at week 16: 4 weeks after the end of treatment. Conclusion: Addition of 1 5-fluorouracil to the nail permeation enhancer Belanyx does not increase the efficacy of the active agent in psoriatic nail dystrophy of this study population. Nail changes are often seen, with pitting, onycholysis, subungual hyperkeratosis, or the oil-drop sign (yellow-red discolouration of the nail bed looking like a drop of oil beneath the nail). Tools such as the Psoriasis Area and Severity Index (PASI) may be used to express disease severity, based on severity of lesions and extent of skin involvement. Narrow-band ultraviolet B (UVB) therapy offers superior efficacy with less risk of burning:NICE recommends that narrow-band UVB phototherapy should be offered to people with plaque psoriasis that cannot be controlled with topical treatments alone. The psoriasis does not respond adequately to a first biological drug, ie 10 weeks after starting treatment for infliximab, 12 weeks for etanercept, and 16 weeks for adalimumab and ustekinumab (primary failure); or. We report efficacy and safety data from a 96-week data cut of RAPID-PsA. For these patients, it was of interest to evaluate the change in mTSS while on CZP following their re-randomisation. CZP treatment (week 12 for patients escaping at week 16, or week 24 for patients switching at week 24). LEI or modified Nail Psoriasis Severity Index (mNAPSI), respectively, were sustained to week 96 (table 3).

Nail Psoriasis: A Review Of Treatment Options

Cosentyx (secukinumab) met the primary endpoints of superiority compared to placebo in patients with difficult-to-treat psoriasis of the nails, palms and soles 1,2 One third of patients with moderate-to-severe palmoplantar psoriasis achieved clear or almost clear skin on their palms and soles after 16 Weeks of treatment with Cosentyx; severity of nail psoriasis decreased by almost a half 1,2 Cosentyx is first approved IL-17A inhibitor to show efficacy in patients with psoriasis in these locations; trial results considered most robust to date Basel, 11 June, 2015 Novartis announced today that Cosentyx (secukinumab) met the primary endpoints in two new clinical studies, showing superior efficacy compared to placebo in patients with psoriasis of the palms, soles and nails, all difficult-to-treat locations of plaque psoriasis. These results, evaluating the efficacy and safety of tofacitinib citrate for the treatment of adults with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, have been selected for oral presentation during the Pearls from the Posters New and Noteworthy Research Finds abstract 2020. Severity Index (NAPSI) at Week 16 in patients with nail psoriasis. The Nail Psoriasis Severity Index (NAPSI) has been designed and successfully implemented to grade the severity of psoriatic nail disease based on these clinical findings. Information about the efficacy of systemic treatments on nail psoriasis is scarce because most studies on skin psoriasis do not focus on the nail changes. PA-02: A randomized, evaluator-blinded, controlled study of efficacy and safety of a small particle hyaluronic acid plus lidocaine for lip augmentation. Both groups were treated after 24 weeks with an optional touch-up 2 weeks later. SPHAL was also significantly better at weeks 12, 16, 20, and 24 compared to no treatment (P.